Claims for Patent: 9,060,940

Summary for Patent: 9,060,940

Title:	Controlled release hydrocodone
Abstract:	A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
Inventor(s):	Oshlack; Benjamin (New York, NY), Huang; Hua-Pin (Englewood Cliffs, NJ), Masselink; John K. (Old Tappan, NJ), Tonelli; Alfred (Congers, NY)
Assignee:	Purdue Pharma L.P. (Stamford, CT)
Application Number:	14/210,565
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,060,940
Patent Claims:	1. A method of providing effective pain relief to a patient in need thereof comprising: obtaining a serum profile of an opioid in the patient, having a plasma level with a C.sub.24/C.sub.max ratio of about 0.55 to about 1.0, by administering orally on a once-a-day basis a controlled release formulation of the opioid to the patient, wherein the controlled release formulation releases an analgesically effective amount of the opioid at an effective rate to provide said serum profile of the opioid, and the opioid is hydrocodone or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the plasma level of the opioid provides a C.sub.24/C.sub.max ratio of 0.55 to 0.85. 3. The method of claim 1, wherein the plasma level of the opioid provides a C.sub.24/C.sub.max ratio of 0.55 to 0.75. 4. The method of claim 1, wherein the plasma level of the opioid provides a C.sub.24/C.sub.max ratio of 0.6 to 0.7. 5. The method of claim 1, wherein the plasma level of the opioid provides a C.sub.24/C.sub.max ratio of 0.7 to 0.85. 6. The method of claim 1, wherein the controlled release formulation comprises a controlled release material comprising a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac and oils. 7. The method of claim 6, wherein the cellulose ether is an alkylcellulose, a hydroxyalkylcellulose, or a carboxyalkylcellulose. 8. The method of claim 1, wherein the controlled release formulation comprises a matrix comprising a hydrophobic material having a melting point of from about 30.degree. C. to about 200.degree. C. 9. The method of claim 1, wherein the controlled release formulation comprises a fatty acid, a fatty alcohol, a glyceryl ester of fatty acid, a wax, a polyalkylene glycol, or a mixture of any of the foregoing materials. 10. The method of claim 9, wherein the matrix comprises the glyceryl ester of a fatty acid. 11. The method of claim 1, wherein the controlled release formulation comprises a matrix comprising microcrystalline cellulose. 12. The method of claim 11, wherein the matrix further comprises hydroxypropylcellulose. 13. The method of claim 1, wherein the controlled release formulation is administered at the initiation of therapy. 14. The method of claim 1, wherein the controlled release formulation is administered at steady-state. 15. The method of claim 1, wherein from about 0.5 mg to about 1250 mg of hydrocodone is administered. 16. The method of claim 15, wherein from about 5 mg to about 60 mg of hydrocodone is administered. 17. The method of claim 1, wherein the pharmaceutically acceptable salt is a bitartrate salt. 18. A method of providing effective pain relief to a patient in need thereof comprising: obtaining a serum profile of an opioid in the patient, having a plasma level of the opioid with a C.sub.24/C.sub.max ratio of about 0.55 to about 1.0, by administering orally on a once-a-day basis a controlled release formulation of the opioid to the patient, wherein the controlled release formulation comprises an effective amount of a controlled release material to release an analgesically effective amount of the opioid at an effective rate to provide said serum profile of the opioid, and the opioid is a bitartrate salt of hydrocodone. 19. A method of providing effective pain relief to a patient in need thereof comprising: obtaining a serum profile of hydrocodone or a pharmaceutically acceptable salt thereof in the patient having a plasma level of the hydrocodone with a C.sub.24/C.sub.max ratio of about 0.55 to about 1.0, and a W.sub.50 of the hydrocodone of between 4 and 22 hours by administering orally on a once-a-day basis a controlled release formulation of the hydrocodone or pharmaceutically acceptable salt to the patient, wherein the controlled release formulation comprises an effective amount of a controlled release material to release an analgesically effective amount of the hydrocodone or pharmaceutically acceptable salt thereof at an effective rate to provide said serum profile of the hydrocodone and said W.sub.50. 20. The method of claim 19, wherein the W.sub.50 is at least 12 hours.